An Overview of the RSV Vaccine Landscape

At the end of May, the FDA approved Moderna’s mRNA 1345 (mRESVIA) vaccine. The immunization is indicated for seniors 60 years of age and older in prevention of lower respiratory tract disease caused by RSV infection. The approval was based from the results of the phase 3 ConquerRSV trial, which demonstrated an 83.7% efficacy against infection.

As there are now 3 FDA-approved RSV vaccines, Contagion has developed a new short series titled, Special Report: Clinical Insights on Moderna's RSV Vaccine. We have asked RSV vaccine investigators to provide more insights about these immunizations. Ann Falsey, MD, professor of Medicine at the University Of Rochester School Of Medicine, and her colleague, Edward Walsh, MD, professor of Medicine at the University Of Rochester School Of Medicine have a peer-to-peer discussion on the impact these vaccines may have in preventing this respiratory illness.

In this first episode, Falsey and Walsh discuss the growing landscape of RSV vaccines.